{"title":"Enhanced transdermal insulin basal release from silk fibroin (SF) hydrogels via iontophoresis.","authors":"Phimchanok Sakunpongpitiporn, Witthawat Naeowong, Anuvat Sirivat","doi":"10.1080/10717544.2022.2096717","DOIUrl":null,"url":null,"abstract":"<p><p>Insulin is the peptide hormone used to treat the diabetes patient. The hormone is normally taken by injection. The transdermal drug delivery system (TDDS) is an alternative route. The silk fibroin (SF) hydrogels were fabricated via solution casting as the insulin matrix. The release and release-permeation experiments of the insulin loaded SF hydrogels were carried out using a modified Franz-diffusion cell at 37 °C for 36 h, under the effects of SF concentrations, pH, and electric field. The release-permeation mechanism through the pig skin was from the Case-II transport with the constant release rate. The diffusion coefficient (D) increased with decreasing SF concentration due to a larger mesh size, and with increasing electric field due to the electroreplusive forces between the insulin and the SF hydrogels against the negatively-charged electrode, and the induced SF hydrogel expansion. The rate and amount of insulin release-permeation became relatively lower as it required a longer time to generate aqueous pathways through the pig skin. The present SF hydrogels are demonstrated here deliver insulin with the required constant release rate, and the suitable amount within a prescribed duration.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"29 1","pages":"2234-2244"},"PeriodicalIF":6.5000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/24/89/IDRD_29_2096717.PMC9848418.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Delivery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10717544.2022.2096717","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Insulin is the peptide hormone used to treat the diabetes patient. The hormone is normally taken by injection. The transdermal drug delivery system (TDDS) is an alternative route. The silk fibroin (SF) hydrogels were fabricated via solution casting as the insulin matrix. The release and release-permeation experiments of the insulin loaded SF hydrogels were carried out using a modified Franz-diffusion cell at 37 °C for 36 h, under the effects of SF concentrations, pH, and electric field. The release-permeation mechanism through the pig skin was from the Case-II transport with the constant release rate. The diffusion coefficient (D) increased with decreasing SF concentration due to a larger mesh size, and with increasing electric field due to the electroreplusive forces between the insulin and the SF hydrogels against the negatively-charged electrode, and the induced SF hydrogel expansion. The rate and amount of insulin release-permeation became relatively lower as it required a longer time to generate aqueous pathways through the pig skin. The present SF hydrogels are demonstrated here deliver insulin with the required constant release rate, and the suitable amount within a prescribed duration.
胰岛素是用于治疗糖尿病患者的肽类激素。这种激素通常以注射方式服用。透皮给药系统(TDDS)是一种替代途径。通过溶液浇注法制造了丝纤维蛋白(SF)水凝胶作为胰岛素基质。在 SF 浓度、pH 值和电场的作用下,使用改进的弗兰兹扩散池在 37 ℃ 下对 SF 水凝胶进行了 36 小时的释放和渗透实验。通过猪皮肤的释放-渗透机制是恒定释放速率下的 Case-II 运输。扩散系数(D)随 SF 浓度的降低而增大,这是由于网眼尺寸增大所致;随电场的增大而增大,这是由于胰岛素和 SF 水凝胶之间对负电荷电极的电重合力以及诱导 SF 水凝胶膨胀所致。胰岛素释放渗透的速度和数量相对较低,因为需要更长的时间才能在猪皮肤上形成水通道。实验证明,目前的 SF 水凝胶能以所需的恒定释放率输送胰岛素,并能在规定的时间内输送适当的胰岛素量。
期刊介绍:
Drug Delivery is an open access journal serving the academic and industrial communities with peer reviewed coverage of basic research, development, and application principles of drug delivery and targeting at molecular, cellular, and higher levels. Topics covered include all delivery systems including oral, pulmonary, nasal, parenteral and transdermal, and modes of entry such as controlled release systems; microcapsules, liposomes, vesicles, and macromolecular conjugates; antibody targeting; protein/peptide delivery; DNA, oligonucleotide and siRNA delivery. Papers on drug dosage forms and their optimization will not be considered unless they directly relate to the original drug delivery issues. Published articles present original research and critical reviews.